The utility of plasma glycated CD59 in predicting postpartum glucose intolerance: A prospective study of women diagnosed with GDM during a period of universal GDM screening.
CD59
biomarker
gestational diabetes
postpartum glucose intolerance
Journal
Diabetic medicine : a journal of the British Diabetic Association
ISSN: 1464-5491
Titre abrégé: Diabet Med
Pays: England
ID NLM: 8500858
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
revised:
12
04
2023
received:
31
07
2022
accepted:
19
04
2023
medline:
17
8
2023
pubmed:
20
4
2023
entrez:
20
04
2023
Statut:
ppublish
Résumé
Gestational diabetes (GDM) is associated with the development of postpartum (PP) glucose intolerance. Plasma glycated CD59 (pGCD59) is an emerging biomarker for the detection of hyperglycaemia. The aim of this study was to assess the ability of PP pGCD59 to predict the development of PP GI as defined by the 2 h 75 g OGTT using the ADA criteria, in a cohort of women diagnosed with prior GDM in the index pregnancy using the 2 h 75 g OGTT at 24-28 weeks of gestation according to the World Health Organization (WHO) 2013 criteria. Of the 2017 pregnant women recruited prospectively 140 women with gestational diabetes had samples for pGCD59 taken PP at the time of the OGTT. The ability of pGCD59 to predict the results of the PP OGTT was assessed using nonparametric receiver operating characteristic (ROC) curves. Women with PP glucose intolerance had significantly higher PP pGCD59 levels compared to women with normal glucose tolerance PP (3.8 vs. 2.7 SPU). PP pGCD59 identified women who developed glucose intolerance PP with an AUC of 0.80 (95% CI: 0.70-0.91). A PP pGCD59 cut-off value of 1.9 SPU generated a sensitivity of 100% (95% CI: 83.9-100), specificity of 16.9% (95% CI: 9.8-26.3), positive predictive value of 22.1% (95% CI: 21.0-22.6), and negative predictive value of 100% (95% CI: 87.4-100). PP fasting plasma glucose generated an AUC of 0.96 (95% CI: 0.89-0.99) for the identification of PP glucose intolerance. Our study found that PP pGCD9 may be a promising biomarker to identify women not requiring PP glucose intolerance screening using the traditional OGTT. While the diagnostic accuracy of pGCD59 is good, fasting plasma glucose remains a better test for the identification of PP glucose intolerance.
Substances chimiques
Blood Glucose
0
Biomarkers
0
CD59 protein, human
101754-01-2
CD59 Antigens
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15121Subventions
Organisme : Wellcome Trust
ID : : 203930/B/16/Z
Pays : United Kingdom
Organisme : NIH HHS
ID : DK101442
Pays : United States
Organisme : NIH HHS
ID : DK089206
Pays : United States
Organisme : NIH HHS
ID : DK62294
Pays : United States
Organisme : NIH HHS
ID : DK095424
Pays : United States
Informations de copyright
© 2023 The Authors. Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK.
Références
Lauenborg J, Mathiesen E, Hansen T, et al. The prevalence of the metabolic syndrome in a danish population of women with previous gestational diabetes mellitus is three-fold higher than in the general population. J Clin Endocrinol Metab. 2005;90(7):4004-4010. doi:10.1210/jc.2004-1713
Kessous R, Shoham-Vardi I, Pariente G, Sherf M, Sheiner E. An association between gestational diabetes mellitus and long-term maternal cardiovascular morbidity. Heart. 2013;99(15):1118-1121. doi:10.1136/heartjnl-2013-303945
Beharier O, Shoham-Vardi I, Pariente G, et al. Gestational diabetes mellitus is a significant risk factor for long-term maternal renal disease. J Clin Endocrinol Metab. 2015;100(4):1412-1416. doi:10.1210/jc.2014-4474
Lowe WL, Scholtens DM, Lowe LP, et al. Association of gestational diabetes with maternal disorders of glucose metabolism and childhood adiposity. JAMA. 2018;320(10):1005-1016. doi:10.1001/jama.2018.11628
Vounzoulaki E, Khunti K, Abner SC, Tan BK, Davies MJ, Gillies CL. Progression to type 2 diabetes in women with a known history of gestational diabetes: systematic review and meta-analysis. BMJ. 2020;369:m1361. doi:10.1136/bmj.m1361
Bellamy L, Casas JP, Hingorani AD, Williams D. Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. Lancet. 2009;373(9677):1773-1779. doi:10.1016/S0140-6736(09)60731-5
Dennison RA, Chen ES, Green ME, et al. The absolute and relative risk of type 2 diabetes after gestational diabetes: a systematic review and meta-analysis of 129 studies. Diabetes Res Clin Pract. 2021;171:108625. doi:10.1016/j.diabres.2020.108625
Fu J, Retnakaran R. The life course perspective of gestational diabetes: an opportunity for the prevention of diabetes and heart disease in women. EClinicalMedicine. 2022;45:101294. doi:10.1016/j.eclinm.2022.101294
American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S14-s31. doi:10.2337/dc20-S002
Stasenko M, Liddell J, Cheng YW, Sparks TN, Killion M, Caughey AB. Patient counseling increases postpartum follow-up in women with gestational diabetes mellitus. Am J Obstet Gynecol. 2011;204:522.e1-522.e6, 522.e6. doi:10.1016/j.ajog.2011.01.057
Ko JY, Dietz PM, Conrey EJ, et al. Gestational diabetes mellitus and postpartum care practices of nurse-midwives. J Midwifery Womens Health. 2013;58(1):33-40. doi:10.1111/j.1542-2011.2012.00261.x
Ko JY, Dietz PM, Conrey EJ, et al. Strategies associated with higher postpartum glucose tolerance screening rates for gestational diabetes mellitus patients. J Womens Health (Larchmt). 2013;22(8):681-686. doi:10.1089/jwh.2012.4092
Davies CS, Harris CL, Morgan BP. Glycation of CD59 impairs complement regulation on erythrocytes from diabetic subjects. Immunology. 2005;114(2):280-286. doi:10.1111/j.1365-2567.2004.02086.x
Ghosh P, Sahoo R, Vaidya A, et al. A specific and sensitive assay for blood levels of glycated CD59: a novel biomarker for diabetes. Am J Hematol. 2013;88(8):670-676. doi:10.1002/ajh.23478
Ghosh P, Vaidya A, Sahoo R, et al. Glycation of the complement regulatory protein CD59 is a novel biomarker for glucose handling in humans. J Clin Endocrinol Metab. 2014;99(6):E999-E1006. doi:10.1210/jc.2013-4232
Ghosh P, Luque-Fernandez MA, Vaidya A, et al. Plasma glycated CD59, a novel biomarker for detection of pregnancy-induced glucose intolerance. Diabetes Care. 2017;40(7):981-984. doi:10.2337/dc16-2598
International Association of Diabetes and Pregnancy Study Groups Consensus Panel. International Association of Diabetes and Pregnancy Study Groups Recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care. 2010;33(3):676-682. doi:10.2337/dc09-1848
Bogdanet D, O'Shea PM, Halperin J, Dunne F. Plasma glycated CD59 (gCD59), a novel biomarker for the diagnosis, management and follow up of women with gestational diabetes (GDM) - protocol for prospective cohort study. BMC Pregnancy Childbirth. 2020;20(1):412. doi:10.1186/s12884-020-03090-9
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2009;32(Suppl 1):S62-S67. doi:10.2337/dc09-S062
Ma D, Luque-Fernandez MA, Bogdanet D, Desoye G, Dunne F, Halperin JA. Plasma glycated CD59 predicts early gestational diabetes and large for gestational age newborns. J Clin Endocrinol Metab. 2020;105(4):e1033-e1040. doi:10.1210/clinem/dgaa087
Bogdanet D, Toth Castillo M, Doheny H, et al. The diagnostic accuracy of second trimester plasma glycated CD59 (pGCD59) to identify women with gestational diabetes mellitus based on the 75 g OGTT using the WHO criteria: a prospective study of non-diabetic pregnant women in Ireland. J Clin Med. 2022;11(13):3895. doi:10.3390/jcm11133895
Benhalima K, Ma DD, Laenen A, Mathieu C, Halperin JA. Plasma glycated CD59 predicts postpartum glucose intolerance after gestational diabetes. Eur J Endocrinol. 2021;185(5):755-763. doi:10.1530/eje-21-0635
Benhalima K, Van Crombrugge P, Moyson C, et al. A modified two-step screening strategy for gestational diabetes mellitus based on the 2013 WHO criteria by combining the glucose challenge test and clinical risk factors. J Clin Med. 2018;7(10):351. doi:10.3390/jcm7100351
Benhalima K, Van Crombrugge P, Moyson C, et al. Prediction of glucose intolerance in early postpartum in women with gestational diabetes mellitus based on the 2013 WHO criteria. J Clin Med. 2019;8(3):383. doi:10.3390/jcm8030383
Battarbee AN, Yee LM. Barriers to postpartum follow-up and glucose tolerance testing in women with gestational diabetes mellitus. Am J Perinatol. 2018;35(4):354-360. doi:10.1055/s-0037-1607284
Bennett WL, Ennen CS, Carrese JA, et al. Barriers to and facilitators of postpartum follow-up care in women with recent gestational diabetes mellitus: a qualitative study. J Womens Health (Larchmt). 2011;20(2):239-245. doi:10.1089/jwh.2010.2233
Diagnostic criteria and classification of hyperglycaemia first detected in pregnancy: a World Health Organization guideline. Diabetes Res Clin Pract. 2014;103(3):341-363. https://pubmed.ncbi.nlm.nih.gov/24847517/
Lauenborg J, Hansen T, Jensen DM, et al. Increasing incidence of diabetes after gestational diabetes: a long-term follow-up in a Danish population. Diabetes Care. 2004;27(5):1194-1199. doi:10.2337/diacare.27.5.1194
Tobias DK, Stuart JJ, Li S, et al. Association of history of gestational diabetes with long-term cardiovascular disease risk in a large prospective cohort of US women. JAMA Intern Med. 2017;177(12):1735-1742. doi:10.1001/jamainternmed.2017.2790
O'Sullivan EP, Avalos G, O'Reilly M, et al. Atlantic DIP: the prevalence and consequences of gestational diabetes in Ireland. Ir Med J. 2012;105(5 Suppl):13-15.
Noctor E, Crowe C, Carmody LA, et al. Abnormal glucose tolerance post-gestational diabetes mellitus as defined by the International Association of Diabetes and Pregnancy Study Groups criteria. Eur J Endocrinol. 2016;175(4):287-297. doi:10.1530/eje-15-1260
Shub A, Miranda M, Georgiou HM, McCarthy EA, Lappas M. The effect of breastfeeding on postpartum glucose tolerance and lipid profiles in women with gestational diabetes mellitus. Int Breastfeed J. 2019;14(1):46. doi:10.1186/s13006-019-0238-5
Carmody L, Egan AM, Dunne FP. Postpartum glucose testing for women with gestational diabetes mellitus: improving regional recall rates. Diabetes Res Clin Pract. 2015;108(3):e38-e41. doi:10.1016/j.diabres.2015.04.005
Claesson R, Ekelund M, Ignell C, Berntorp K. Role of HbA1c in post-partum screening of women with gestational diabetes mellitus. J Clin Transl Endocrinol. 2015;2(1):21-25. doi:10.1016/j.jcte.2014.10.003